



Review

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Milena Rizzo*

Non-coding RNA Group, Functional Genetics and Genomics Lab, Institute of Clinical Physiology (IFC), CNR, Pisa, Italy



ARTICLE INFO

Keywords:

miRNAs
Docetaxel resistance
Prostate cancer
Drug resistance
Taxane

ABSTRACT

One of the main problems with the treatment of metastatic prostate cancer is that, despite an initial positive response, the majority of patients develop resistance and progress. In particular, the resistance to docetaxel, the gold standard therapy for metastatic prostate cancer since 2010, represents one of the main factors responsible for the failure of prostate cancer therapy. According to the present knowledge, different processes contribute to the appearance of docetaxel resistance and non-coding RNA seems to play a relevant role in them. In this review, a comprehensive overview of the miRNA network involved in docetaxel resistance is described, highlighting the pathway/s affected by their activity.

1. Introduction

Prostate cancer (PCa) is the second most frequent cancer in men [1]. Despite the high long-term survival in localized PCa, metastatic PCa remains largely incurable. One of the main problems when PCa progresses from localized to advanced disease is that patients who initially benefit from a specific treatment commonly become refractory to therapy. The treatment for advanced PCa initially consists of androgen deprivation therapies (ADT) achieved by surgical castration (orchiectomy) or chemical castration using agents targeting androgen receptor (AR) signaling (e.g. AR antagonist, gonadotropin-releasing hormone agonist, etc.) [2]. Unfortunately, a high percentage of patients, after an initial positive response, experiences recurrence and becomes insensitive to ADT and progresses to a second phase named castration resistant prostate cancer (CRPC). Since 2010, the gold standard therapy for CRPC was docetaxel (DCT) chemotherapy [3–5] in combination with the second-generation anti-androgens such as enzalutamide or inhibitors of androgen biosynthesis such as abiraterone [6–8]. Even though the use of these drugs has improved clinical outcomes prolonging the lifespan, many patients develop resistance. Although the exact molecular mechanisms of DCT resistance are not completely clarified, in the last few years several lines of evidence have highlighted the important role that microRNAs (miRNAs) play in the sensitivity to this drug. miRNAs are small single stranded RNA molecules that have a fundamental role in the regulation of gene expression at the post-transcriptional level in all

physiological and pathological aspects of cell biology. miRNAs that play a role in DCT resistance in PCa were last summarized in 2015 [9] and partially addressed by Li et al. [10] and Razdan et al. [11]. Recently several new miRNAs have been identified contributing to this phenomenon.

The aim of this review is to outline the miRNAs that have to date been demonstrated to counteract or increase DCT resistance in PCa, pointing out the mechanisms whereby they exert their role.

2. Mechanisms of docetaxel resistance in prostate cancer

2.1. Mechanisms of docetaxel action

DCT is a second-generation chemotherapeutic drug of the taxane family. At the molecular level it binds with high affinity to β -tubulin, disrupting microtubule dynamics and thereby affecting cytoskeleton functions during mitosis. As a consequence, the normal progression of the cell cycle is impaired, resulting in G2/M arrest leading to inhibition of proliferation and cell death [12].

Despite their mitotic function, taxanes have also been reported to affect non-mitotic functions such as alterations of several signaling pathways or inhibition of intracellular trafficking [13]. It has been shown that DCT induces apoptosis via BCL2 phosphorylation followed by caspase activation [14,15] or inhibits cell proliferation by down-regulating ERK1/2 signaling [16]. Moreover, taxanes inhibit ligand-

* Corresponding author at: Non-coding RNA Group, Functional Genetics and Genomics Lab, Institute of Clinical Physiology (IFC), CNR, via Moruzzi 1, 56124 Pisa, Italy

E-mail address: milena.rizzo@ifc.cnr.it.

<https://doi.org/10.1016/j.bbcan.2020.188481>

Received 25 August 2020; Received in revised form 4 November 2020; Accepted 12 November 2020

Available online 17 November 2020

0304-419X/© 2020 Elsevier B.V. All rights reserved.

induced AR nuclear translocation and hence the downstream activation of AR target genes [17,18].

2.2. Mechanisms of docetaxel resistance

In this section the main mechanisms of DCT resistance are described, discussing in greater detail the ones in which miRNAs involved in DCT resistance exert a regulatory role.

The more consolidated mechanisms of DCT resistance in PCa are (Fig. 1):

2.2.1. Alterations of microtubules

It has been reported that structural/functional alterations of microtubules targeted by DCT have an impact on drug efficacy [19,20]. Upregulation of β III-tubulin [21,22] as well as mutations of the β - or α -tubulin genes [23] or modifications of the microtubule-associated proteins [24] can modify either the microtubule dynamics (β III-tubulin-containing microtubules are less stable and exhibit aberrant dynamics) or the DCT binding capability. As a consequence, cancer cells become less sensitive to DCT toxicity.

2.2.2. Drug efflux transporter upregulation

The ATP-binding cassette (ABC) transporters are a superfamily of drug efflux pumps involved in the transmembrane transport of intracellular substrates [25]. Some members of this family present a broad drug specificity and are involved in chemoresistance as they extrude drugs causing a decrease of drug ability to target the cells [19,20]. Indeed, the upregulation of some members of this family such as ABCB1 (MDR1), ABCC1 (MRP1) and ABCC4 (MRP4) has been associated with

DCT resistance in PCa by increasing DCT extrusion [26–29].

In addition, several other pathways have been associated to DCT resistance in PCa.

2.2.3. Survival pathways activation/apoptosis escape

Deregulation of several proteins involved in signaling pathways that increase tumor cells survival or that allow cells to evade apoptosis are associated to DCT resistance in PCa. It has been shown that anti-apoptotic proteins belonging to the BCL2 family such as BCL-2, BCL-XL and MCL-1 are associated with DCT resistance probably by affecting the homodimerization of BAX or BAK proapoptotic proteins and hence the DCT-induced apoptosis process [30,31]. Indeed, the inhibition of the BCL2 family sensitizes PCa cells to DCT [32,33]. The upregulation of chaperon molecules such as clusterin, Hsp27 and Hsp90 has also been associated with DCT resistance [31,34]. In particular, clusterin exerts a key role in preventing apoptosis induced by cytotoxic drugs (such as DCT) by sequestering BAX [35,36]. Some therapeutic approaches based on targeting clusterin are under evaluation [37]. Docetaxel resistance was also found to be associated with PAR1 activation that reduce DCT-induced apoptosis by NF- κ B activation [38]. Several pathways associated with PCa cell survival have also been linked to DCT resistance. Activation of the PI3K/AKT pathway is often observed when PCa progresses toward a resistant disease and even in this case therapeutic approaches targeting this signal pathway have shown promising results [39–41]. In the same way the MAPK/ERK pathway is also activated in DCT resistant (DCT^R) PCa cells and plays a role in DCT resistance [16,42,43]. Vidal et al. identified GATA2 as a regulator of chemotherapy resistance in PCa [44,45]. Authors demonstrated that GATA2 acts as a transcriptional activator of IGF-2 that in turn activates IGF-1R and INS-R




Fig. 1. Schematic overview of the mechanisms of DCT resistance in PCa. AR, androgen receptor; ARE, androgen response element; CAF, cancer-associated fibroblasts; DCT, docetaxel; EMT, epithelial mesenchymal transition; EMT-TF, epithelial mesenchymal transition transcription factors; ROS, Reactive oxygen species; TAM, tumor-associated macrophage; TME, tumor microenvironment.

and the downstream signal pathways leading to cell proliferation and survival. Finally, also Notch, Hedgehog, JNK and WNT/ β -Catenin signaling pathways have been associated to DCT resistance [19,31,46].

2.2.4. Altered AR signaling

As previously explained (paragraph 2.1), DCT affects AR signaling by altering microtubule-associated AR nuclear translocation. Indeed, it has been demonstrated that DCT does not impair the nuclear accumulation of AR splice variants (such as AR-V7) [47] and that AR-V7 is upregulated in DCT^R PCa cell lines [48]. However, the impact of AR splice variants on DCT resistance is a matter of debate [49].

2.2.5. Activation of antioxidant response

Taxanes have been shown to trigger reactive oxygen species (ROS) formation in cancer cells. An excessive ROS concentration may lead to apoptosis activation [50] contributing to the toxicity of taxanes [51]. It has been shown that paclitaxel induces alterations in the mitochondrial membrane that affect cytochrome C release and reactive oxygen species (ROS) production leading to apoptosis [52]. In turn, in response to taxanes-induced ROS production, cancer cells activate an antioxidant response that enables cells to resist the cytotoxicity of taxanes [50,53]. Indeed, the upregulation of antioxidant enzymes has been associated to DCT resistance. Zhang et al. reported that high BIM-1 expression, that predicts poor prognosis in PCa patients, increases DCT resistance by activating an antioxidant response that reduces ROS and cell death [50]. Intriguingly, it has been shown that the antioxidant response and the consequent ROS decrease mediated DCT resistance by also activating pro-survival pathways. Indeed, Zhang et al. demonstrated that high SOD2 level in DCT^R cells determined a ROS reduction that in turn impaired the arrestin-1 dependent insulin-like growth factor-I receptor (IGF-1R) degradation [54]. IGF-1 signaling is believed to play a prominent role in tumor growth and drug resistance [55].

2.2.6. Adverse tumor microenvironment (TME)

The DCT resistance, and in general taxanes resistance, is a complex phenomenon dependent on the activation of several molecular pathways both in cancer cells and in the surrounding tumor microenvironment (TME). The TME is characterized by aberrant angiogenesis and hence by a chaotic blood flow that not only impairs drug distribution but also the delivery of oxygen and nutrients, generating regions of tumor hypoxia that contribute to taxanes resistance [30,56]. Indeed, hypoxia triggers the activation of the hypoxia-inducible factor 1 α (HIF-1 α) that in turn activates the so-called hypoxic response and several HIF-1 α dependent pathways such as autophagy and epithelial to mesenchymal transition (EMT) [57,58]. All these pathways, including the hypoxic response [57,59,60], contribute to taxanes resistance (see below). The TME is also characterized by the presence of cytokines and growth factors (such as IL-6, TGF- β) produced by the cells of the tumor stroma (such as tumor-associated macrophages (TAMs) and the cancer-associated fibroblasts (CAFs)) that further reinforce the activation of the above-mentioned pathways enhancing resistance [30,56,57].

2.2.7. Autophagy induction

Although autophagy is a process that in normal condition has a protective role as it facilitates the removal of harmful protein aggregates and cellular components, in cancer cells it can support growth and survival and so it is responsible for cancer progression and drug resistance [61]. Several lines of evidence demonstrated that an increased activation of autophagy supports DCT resistance in PCa [62–65]. E.g. upregulation of either FOXM1 [66] or NPRL2 [67] induces an autophagy-dependent DCT resistance through the regulation of the AMPK/mTOR pathway in PCa.

2.2.8. Epithelial to mesenchymal transition (EMT)

Recently, an increasing number of reports support the involvement of the reactivation of EMT in the chemoresistance of cancer cells

[58,68]. Empirical evidence suggested that cells undergoing EMT acquire stem cell-like property, thus sharing key signaling pathways and the drug resistance phenotype with cancer stem cells (CSCs) (see below) [69,70]. EMT implies a transcriptional reprogramming driven by specific transcription factors (EMT-TFs) whose activation is likely to be linked to cellular stemness and hence to drug resistance. Moreover, it has become clear that EMT-TFs (such as SNAI, TWIST and ZEB families) might have a non-EMT dependent effects playing a role in several drug resistance pathways such as i) inhibition of proapoptotic/activation of prosurvival pathways, ii) induction of drug detoxifying enzymes and iii) induction of drug efflux pumps (ABC transporters) [58]. EMT markers are associated with PCa worst prognosis [71,72]. Marin-Aguilera et al. demonstrated that DCT^R PCa cells express high EMT and stem-like cell markers [73]. They also proved that DCT treatment determined the enrichment of a subpopulation of PCa cells with EMT/stem-like gene expression signature that was less sensitive to DCT. Finally, they demonstrated that the ZEB1 silencing was able to revert the EMT/stem-like genes expression (restored CDH1 and suppressed CD44 expression) and, as a consequence, to decrease DCT resistance. ZEB1 plays a key role in drug resistance [74]. Its role in DCT resistance was confirmed by Hanrahan et al. who demonstrated that ZEB1 is a driver of EMT and DCT resistance in PCa through E-cadherin repression [75]. Finally, ZEB1 expression can confer DCT resistance by modulating the drug efflux pump MRP4 expression [76], suggesting a non-EMT dependent role of EMT-TFs in PCa DCT resistance.

2.2.9. Cancer stem cells (CSC)

The existence of a subpopulation of cancer cells with stemness characteristics (such as self-renewal) has been associated to drug resistance. CSCs, situated in a specialized microenvironment (niche) that contributes to their formation and maintenance, present/acquire several properties that enable them to resist to drug treatment [77,78]. In particular, these properties are: I) high survival capacity (due to active DNA damage response systems, anti-apoptotic/pro-proliferative molecules activation and high telomerase activity); II) the ability to adopt a quiescent status; III) elevated drug export due to the high expression/activity of the drug efflux pumps; IV) low level of ROS maintenance; V) stemness induction (due to EMT/stem-like pathways activation) [78]. Evidence suggested that DCT^R PCa cells and tissues are characterized by the increased presence of CD44⁺ and/or CD133⁺ CSC cells able to resist DCT toxicity by activating specific signaling pathway. It has been shown that the increased CD44 in DCT^R PCa cells promotes migration and invasion via induction of the HIPPO-YAP signaling pathway [79]. Talukdar et al. isolated prostate cancer stem cells (characterized by the expression of CD44/CD133 and self-renewal associated genes) and demonstrated that these cells were resistant to DCT [80]. The DCT resistance was due to the MDA-9 dependent activation of both STAT3 and NOTCH/cMYC pathways that determined the ABCB1 transporter upregulation with the consequent increase of drug efflux. The efficacies of prostate CSC eradication in reverting DCT resistance was demonstrated in vitro by several studies with different compounds [81,82], including STAT3 inhibitors [83,84].

3. Role of miRNAs in the mechanisms of docetaxel resistance

An increasing number of miRNAs have been discovered to play a role in the appearance of DCT resistance. Here, the miRNAs that play a role in PCa DCT resistance are described discussing the mechanism in which they are involved (Fig. 2, Table 1).

3.1. Survival pathways activation/apoptosis escape

Several miRNAs affect DCT sensitivity by targeting genes that inhibit apoptosis or activate prosurvival pathways. Niu et al. demonstrated that insulin-like growth factor-I (IGF-1) induces DCT resistance in PCa cells by downregulating miR-143 expression [85]. Indeed, miR-143




Fig. 2. Schematic overview of the miRNAs involved in the mechanisms of PCa DCT resistance. miRNAs are grouped according to their role in DCT resistance. miRNAs that increase the DCT resistance are indicated in bold whereas miRNAs that sensitize cells to DCT are indicated in normal text. miRNA ID of the reference paper is indicated in the figure. miR-204 was reported with two different IDs (one in brackets) as its involvement in drug efflux transporters regulation was demonstrated by two different papers that use different miRNA ID. miR-125p is in grey as the authors only hypothesized its involvement in EMT.

downregulation induced by IGF-1 leads to the derepression of the miR-143 targets IGF-1 receptor (IGF-1R) and insulin receptor substrate 1 (IRS1). The consequent activation of the downstream signaling molecules (such as the transcription of the vascular endothelial growth factor, VEGF) determines DCT resistance through activation of prosurvival pathways. Indeed, miR-143 overexpression sensitizes PCa cells to DCT both *in vitro* and *in vivo*. The miR-143 ability to enhance DCT sensitivity in PCa was previously demonstrated by Xu et al., identifying the miR-143 direct target KRAS as the possible mediator of miR-143 activity [86]. miR-183 is involved in PCa DCT resistance by regulating cell survival pathways [87]. It is indeed involved in a regulatory circuit together with lncRNA CASC2 and SPRY2: the overexpression of both mRNAs increase DCT sensitivity, mainly by affecting DCT-induced decrease of cell viability and apoptosis of PCa cells. In particular, CASC2 acts as a competing endogenous RNA (ceRNA) of miR-183 that in turn determines the derepression of its direct target SPRY2. SPRY2 is a well-known receptor tyrosine kinase (RTK) inhibitor [88] and the authors demonstrated that CASC2 overexpression inhibited ERK signaling and that this inhibition is partially attenuated by SPRY silencing [87]. Finally, Shi et al. demonstrated that miR-21 is highly expressed in PCa DCT^R cells and its knock down in *in vitro* model increased DCT sensitivity through its target PDCD4 [89]. Indeed, miR-21 silencing or PDCD4 overexpression inhibited cell proliferation and increased apoptosis in DCT^R cells [89]. Intriguingly, a more recent paper demonstrated that miR-21 is regulated by IL-6 and that IL-6 inhibits PDCD4 through miR-21 activation [90]: these data support the association between IL-6 secretion and DCT resistance in PCa [91].

Regarding escape of apoptosis, some miRNAs play a role in DCT sensitivity by regulating antiapoptotic proteins. miR-205 and miR-31 are downregulated in DCT^R PCa cells and their overexpression increases DCT sensitivity by inhibiting the antiapoptotic genes BCL-W and E2F6 respectively thus promoting DCT-induced apoptosis [92]. In a later

paper the same authors demonstrated that miR-205 downregulation, caused by promoter hypermethylation, determined the derepression of its target EZH2 [93]. EZH2, in turn, induced miR-31 promoter hypermethylation and, as a consequence, miR-31 downregulation. Therefore, the EZH2-dependent epigenetic silencing of miR-205/-31 plays a role in the mechanism of PCa DCT resistance, consistent with the positive correlation between high expression EZH2 level and PCa progression [94]. Similarly, miR-195 is downregulated in DCT^R PCa cells, and its overexpression promotes DCT-induced apoptosis by inhibiting its direct target clusterin, which is known to play a role in the apoptosis-avoidance mechanism of DCT resistance [95]. miRNAs also affect DCT-induced apoptosis by regulating proteins that have multiple roles beside apoptosis. miR-223-3p attenuates the DCT-induced apoptosis directly regulating FOXO3 [96]. FOXO proteins are a family of transcription factors implicated in the regulation of cellular homeostasis (including apoptosis) and chemoresistance. Also miR-323 decreases the DCT-induced apoptosis probably through its direct target p73, which is a tumor suppressor belonging to the p53 family that modulates several aspects of tumor biology including drug resistance [97]. Similarly, miR-4735-3p, probably by inhibiting MEKK1 expression, may suppress DCT-induced apoptosis allowing PCa cells survival [98]. Finally, Wang et al. demonstrated that high miR-375 levels confer DCT resistance by decreasing apoptosis both in PCa *in vitro* and in a xenograft model [99]. The authors identified SEC23A and YAP1 as possible miR-375 targets mediators in DCT resistance.

Some studies discovered miRNAs that influence DCT resistance by inducing/repressing apoptosis even though they did not identify the target/s mediator/s. Lin et al. screened 1280 miRNAs (by miRNAs mimic transfection) in PCa cells treated with DCT and found that miR-217 and miR-181b-5p mimic enhanced DCT-induced apoptosis [100]. On the contrary, miR-181a was upregulated in DCT^R PCa cells and its inhibition in these cells increased apoptosis possibly by increasing p53

Table 1
miRNAs involved in DCT resistance in Prostate Cancer.

miRNA paper ID ¹	miRNA current ID ²	Biological process	Validated target/s	DCT resistance ³	Reference
miR-143	miR-143-3p	Cell survival	IGF-1R*, IRS1* KRAS	decrease decrease	[85] [86]
miR-183	miR-183-5p	Cell survival/ apoptosis	SPRY2	increase	[87]
miR-21	miR-21-5p	escape	PDCD4	increase	[89]
miR-205 [#]	miR-205-5p	Apoptosis escape	BCL-W	decrease	[92, 93]
miR-31	miR-31-5p		E2F6	decrease	
miR-195	NI		clusterin	decrease	[95]
miR-223-3p	-		FOXO3	increase	[96]
miR-323	miR-323a-3p		p73	increase	[97]
miR-4735-3p	-		MEKK1	increase	[98]
miR-375	NI		SEC23A*, YAP1*	increase	[99]
miR-217	NI		-	decrease	[100]
miR-181b-5p	-		-	decrease	
miR-181a	miR-181a-5p		-	increase	[101]
miR-204 [#]	miR-204-5p	Apoptosis escape, EMT-TF, drug efflux	ZEB1 SIRT1*	decrease decrease	[102] [105]
miR-129-5p	-	Apoptosis escape, cell survival, migration/invasion	CAMK2N1	increase	[106]
miR-138 [#]	miR-138-5p	Apoptosis escape, cell spreading	KINDLIN-2	decrease	[107]
miR-145-5p	-	Apoptosis escape, migration/invasion	AKAP12	decrease	[110]
miR-125a-3p	-	Apoptosis escape, EMT	MTA1	decrease	[113]
miR-133b	-	Apoptosis escape, drug efflux	HuR	decrease	[111]
miR-204-5p [#]	-	Drug efflux, migration/invasion	ACSL4	decrease	[114]
miR-34a-5p [#]	-		JAG1	decrease	[115]
miR-34a-5p [#]	-		-	decrease	
miR-193a-5p	-	Antioxidant response	BACH2	increase	[116]
miR-200c	miR-200c-3p	EMT	ZEB1/2*	decrease	[118]
miR-205 [#]	miR-205-5p		-	decrease	
miR-27b	miR-27b-3p		ZEB1	decrease	[119]
miR-34a [#]	miR-34a-5p		-	decrease	
miR-101-3p	-	Cancer stem cells	EZH2*	decrease	[120]
miR-138-5p [#]	-		-	decrease	
miR-328	NI	Others	PAK6	decrease	[122]
miR-200b	miR-200b-3p		-	decrease	[121]

¹miRNAs ID indicated in the reference paper.

²miRNAs ID indicated in the latest miRbase release (22.1, 2018) if different from the reference paper. NI, not indicated in the latest miRbase release. In the manuscript the ID indicated in the reference paper was used.

³In this column miRNA that act increasing or decreasing DCT resistance in PCa were indicated.

[#]miRNAs involved in more than one mechanism of DCT resistance.

*miRNAs targets that have not been validated in the reference paper. EZH2 has been validated only as miR-138-5p target.

phosphorylation [101].

Finally, several miRNAs are involved in DCT resistance by affecting other mechanisms in addition to apoptosis. miR-204, that is downregulated in DCT^R PCa cells and chemoresistant PCa tissues, if overexpressed, sensitizes cells to DCT and promotes apoptosis, at least in part, by inhibiting ZEB1 [102]. It is known that ZEB1 plays a crucial role in inhibiting apoptosis [103,104] but the authors also discussed the master role of ZEB1 (and miR-204) in EMT and EMT driven drug resistance (paragraph 2.2.8). In addition, a previous work identified miR-204 as a part of a circuit involved in PCa DCT resistance [105]. More precisely, miR-204 is sponged by the lncRNA UCA1 and regulated SIRT1 in PCa. The SIRT1 upregulation due to UCA1 overexpression (that determines miR-204 sequestration/SIRT1 release) has been shown to promote DCT resistance by decreasing DCT-induced apoptosis (through caspase 3 activation) and by increasing ABCB1 (MDR1) expression. Wu et al. demonstrated that miR-129-5p, through the inhibition of CAMK2N1, attenuates DCT efficacy not only by decreasing apoptosis (due to BCL2 induction and BAX repression) but also by increasing cell survival (with an increase of p-ERK1/2 and p-MEK) and invasion/migration potential of PCa cells [106]. miR-138 enhances DCT resistance in PCa cells by inhibiting DCT-induced apoptosis and increasing integrin β 1-mediated cells spreading in PCa cells [107]. Authors demonstrated that miR-138 overexpression, by targeting KINDLIN-2, enhances DCT-induced apoptosis. KINDLIN-2 is a member of a protein family whose members are key regulators of the adhesive function mediated by integrin. Indeed, the downregulation of KINDLIN-2, acting on β 1 integrin, reinforces the reduction of cells spreading induced by DCT. The cell spreading downstream of β 1 integrin signaling has been shown to promote chemoresistance [108,109]. Xue et al. demonstrated that the lncRNA MALAT1 enhances DCT resistance in PCa cells by miR-145-5p-mediated regulation of AKAP12 [110]. The authors proved the existence of this axis in DCT^R PCa cells and, by modulating all the component of the axis, they demonstrated that MALAT1, via miR-145-5p/AKAP12, plays a role in apoptosis and in the migratory/invasive capability of DCT^R PCa cells. Ectopic expression of miR-133b promoted DCT-induced apoptosis (by BLC2/survivin decrease and BAX/cleaved caspase 3 decrease) and ABCG2 (MXR) expression [111]. The target mediator of the miR-133b activity is human antigen R (HuR). HuR is a RNA-binding protein that regulates the stability, translation and nucleus-to-cytoplasm translocation of its target mRNAs [112]. Several HuR targets encode proteins important for tumorigenesis. Finally, miR-125a-3p regulates DCT-induced apoptosis and DCT sensitivity through its target MTA1, a protein that plays a pivotal role in signal regulation by modifying the acetylation status of crucial genes [113]. Moreover, authors noticed that miR-125a-3p overexpressing cells exhibited a round shape that rendered these cells more similar to epithelial cells rather than mesenchymal, hypothesizing an EMT.

3.2. Modification of drug efflux transporters

One of the more consolidated mechanism of DCT resistance is drug efflux due to the upregulation of the ABC transporter (paragraph 2.2.2). Some miRNAs modulated DCT resistance by regulating the ABC transporters expression, as already seen for miR-204 that also acts by targeting ABCB1 (MDR1) expression (paragraph 3.1). Another more recent study identified miR-204-5p (this is the current ID of miR-204 according to the latest miRbase release -22.1, October 2018-, see Table 1) as a regulator of ABC transporters [114]. In particular, the authors discovered that lncRNA NEAT1, that is upregulated in DCT^R PCa cells and tissues, induces DCT resistance by sponging both miR-204-5p and miR-34a-5p which in turn release their common target ACSL4. ACSL4 is involved in drug resistance by distinct pathways. In this work the authors demonstrated that its upregulation due to NEAT1/miRNAs alteration in DCT^R PCa cells enhanced ABCG2 (MRX) and ABCC4 (MRP4) expression and also invasion and migration. In a similar work, Ma et al. demonstrated that miR-34a-5p is involved in another circuit that affects

DCT resistance through the regulation of the ABC transporters together with lncRNA DANCR and JAG1 [115]. Specifically, DANCR, by sponging miR-34a-5p, derepresses JAG1 that in turn promotes DCT resistance by inducing the increase of ABCB1 (MDR1) and ABCC4 (MRP4) expression and, also in this case, invasion and migration. Of note, DANCR and JAG1 are upregulated while miR-34a-5p is downregulated in DCT^R PCa tissues.

3.3. Antioxidant response activation

A recent work demonstrated the involvement of a miRNA (miR-193a-5p) in the regulation of the antioxidant responses induced by DCT treatment and in DCT resistance in PCa [116]. Indeed, miR-193a-5p mediated the heme oxygenase-1 (HO-1) induction after DCT treatment. HO-1 is a cytoprotective enzyme with antioxidant properties [117]. During oxidative stress caused by chemotherapeutic agents, cancer cells induce antioxidant factors and reduce apoptosis to protect against the oxidative injury. Authors demonstrated that the DCT-induced miR-193a-5p inhibits BACH2, a repressor of HO-1. They also showed that ectopic expression of miR-193-5p reduces the apoptosis induced by oxidative stress (H₂O₂ treatment). Indeed, they demonstrated that the HO-1 upregulation counteracts in part the DCT-induced apoptosis by inducing BCL2 upregulation and BAX downregulation. Finally, they also validated the axis in xenograft model, in which the injected PCa cells depleted of miR-193a-5p were more sensitive to DCT toxicity than the injected control cells.

3.4. EMT activation

As already mentioned, cancers cells undergoing EMT exhibit increased DCT resistance (paragraph 2.2.8). Indeed, I previously reported that two miRNAs that affected DCT sensitivity by modulating DCT-induced apoptosis also act probably by inducing EMT (miR-125a-3p) or regulating ZEB1 (miR-204) an important EMT transcription factor (paragraph 3.1). Pühr et al. demonstrated that two members of the miR-200 family (miR-200c and miR-205), which are known ZEB1/2 direct inhibitors, were downregulated in DCT^R PCa cells that underwent EMT (proved by the activation of EMT markers (including ZEB1/2) and by the increase of invasive/migratory potential) [118]. Authors also demonstrated that the miRNAs overexpression caused ZEB1/2 downregulation and the consequent E-cadherin upregulation. In another work, Zhang et al. demonstrated that ZEB1 expression was also regulated by miR-27b and miR-34a (this is the previous ID of miR-34a-5p according to the latest miRbase release -22.1, October 2018-, see Table 1) [119]. In particular, the overexpression of the two miRNAs in DCT^R PCa cells in which they are downregulated, increases the DCT sensitivity possibly by inhibiting EMT through ZEB1 direct inhibition and the consequent E-cadherin upregulation and vimentin downregulation. Furthermore, DCT^R PCa cells overexpressing miR-27b/-34a became more sensitive to DCT toxicity also in a xenograft model.

3.5. Cancer stem cells

Increasing evidence indicates that the presence/formation of a sub-population of cells within the tumor/tumor microenvironment with stemness characteristics (cancer stem cells, CSC) impairs drug efficacy, including DCT in PCa (paragraph 2.2.9). miRNAs could play a role in this phenomenon as shown by Qui et al. who demonstrated that DCT^R PCa cells are characterized by the enrichment of cells with stemness characteristics [120]. In addition, these cells showed a strong EZH2 upregulation that was fundamental for the formation of CSC population in DCT^R PCa cells. Indeed, EZH2 inhibition decreased the number of CSC cells restoring DCT sensitivity. The authors showed that EZH2 is putatively targeted by miR-101-3p/-138-5p (EZH2 has been validated as miR-138-5p target by others). The two miRNAs not only are downregulated in DCT^R PCa cells, but their overexpression induces

EZH2 inhibition and restores cells sensitivity to DCT, suggesting that they play a role in CSC formation/DCT resistance by regulating EZH2. It is of note that the EZH2-dependent epigenetic regulation might also be involved in miR-205/-31 DCT resistance (paragraph 3.1), even though in this case authors hypothesized an activating role of EZH2 on stem cell markers expression, thus excluding a PRC2 complex-dependent activity.

3.6. Others

Finally, also miR-200b [121] and miR-328 [122] affected DCT sensitivity of PCa cells. miR-200b regulates (directly or indirectly) BMI-1 expression and both miR-200b overexpression or BMI-1 silencing increase DCT sensitivity of PCa cells. As previously described (paragraph 2.2.5), BMI-1 is involved in DCT resistance by activating the antioxidant defense allowing PCa cells to survive the treatment [50]. Thus, it is possible that miR-200b may act on this mechanism of DCT resistance through BMI-1, even though other mechanisms cannot be excluded (e.g. EMT induction). In the same way, miR-328 overexpression increases DCT sensitivity as well as its target (PAK6) silencing. PAK6 has been already associated to DCT-resistance [123] and authors hypothesized that the mechanism could be ascribed to cytoskeleton inhibition, given that PAK6 signaling play an important role in cytoskeleton remodeling [124].

4. Clinical implications and concluding remarks

miRNAs play a relevant role in the regulation of the expression of coding/non coding genes that are fundamental for the development of DCT resistance in PCa. Considering the existing literature, miRNAs are involved in almost all the known mechanisms of DCT resistance. The majority of the miRNAs discovered as DCT-resistance regulators/modulators in PCa and hence object of this review (DCT-miRNAs) are involved in the fundamental pathways at the basis of “cell survival”, in particular “apoptosis avoidance”. As a single miRNA can regulate hundreds of genes, it is conceivable that the same miRNA can modulate DCT resistance by acting on multiple pathways. Indeed, several DCT-miRNAs affect more than one biological process associated to DCT-resistance (e.g. miR-204-5p, miR-34a-5p, etc.). For this characteristic, miRNAs represent potentially strong regulators of drug resistance pathways. This concept is supported by a conspicuous number of reports, especially in PCa. Indeed, miRNAs play a role in antiandrogen [125], cisplatin [126] and paclitaxel [127,128] resistance. Moreover, miRNAs, modulate radiosensitivity of PCa cells by regulating mitochondrial antioxidant enzyme [129], hypoxia-induced autophagy [130], EMT [131] and cyclin D1-E1/pRB/E2F1 pathway [132].

Given the proven relevance of miRNAs in drug resistance regulation, the DCT-miRNAs could represent ideal therapeutic targets. Since DCT, in combination with second generation hormone therapy, is still the only therapeutic choice for metastatic CRPC (mCRPC), new therapeutic approaches based on DCT-miRNAs modulation could be attractive to overcome DCT resistance and/or to increase the current therapy efficacy when used in combination. The silencing of a miRNA whose overexpression increases drug resistance or the replacement of a miRNA whose downregulation decreases drug sensitivity could restore the sensitivity of cancer cells to a specific treatment. The miRNA overexpression is obtained using synthetic miRNA mimics, i.e. double-stranded small RNA molecules that match the corresponding miRNA sequences. On the hand, the miRNA silencing is achieved using anti-miRs, single strand RNA molecules whose sequences are complementary to the corresponding miRNA and block its function by strongly binding to it. Several strategies have been developed to efficiently deliver the therapeutic miRNA/antimiRNA molecules to the target cells in vivo, including chemical modifications to increase their stability or the use of viral or non-viral (nanoparticles) vectors (for review see [133,134]). In particular, nanoparticles seem to be promising as they have several

advantages, such as systemic stability and efficient delivery [135,136]. Intriguingly, two different miRNA-based nanoparticles have been developed to increase the DCT cytotoxicity in PCa using DCT-miRNAs. Nagesh et al. [137] demonstrated that magnetic nanoparticles that bind miR-205 sensitized PCa cells to DCT. Furthermore, pH and glutathione sensitive nanocarriers for co-delivery of DCT and rubone (a miR-34 activator) efficiently increase DCT cytotoxicity in DCT resistant PCa cells *in vitro*, in 3D spheroid model and in xenograft model [138]. The possibility to develop nanoparticles carrying more than one compounds is particularly interesting when a therapy in combination with DCT is considered.

Another aspect is that the identification of the gene networks regulated by miRNAs related to drug resistance could allow the discovery of multiple potentially targetable genes/pathways. A series of pre-clinical/clinical studies regarding compounds that target the genes and/or pathways regulated by DCT-miRNAs corroborate the previous statement. E.g. the ABC1 transporter inhibition obtained using its inhibitors reversan and MK571 sensitized PCa cells to DCT [139]; the HDAC inhibitor mocetinostat interfered with ZEB1 expression and restored the DCT chemosensitivity in DCT resistant PCa cells partially reversing the EMT phenotype [140]; the BCL-W inhibitors ABT-263/ABT-737 significantly increased the antitumor effect of DCT on DCT PCa resistant cells [33]; custirsens, an antisense oligonucleotide that inhibit the production of clusterin, showed promising results in a randomized phase III trials in combination with cabazitaxel and prednisone in mCRPC PCa patients that progress after DCT therapy [141]. In addition, several existing compounds targeting DCT-miRNAs targets could be evaluated as possible treatment to potentiate DCT cytotoxicity. The inhibition of SIRT1 (one of the miR-204 targets) could restore DCT sensitivity by enhancing DCT-induced apoptosis. The SIRT1 inhibitors nicotinamide and sirtinol have been shown to decrease PCa cells growth and viability [142]. Similarly, EZH2 (the miR-138-5p direct target) inhibition could increase DCT sensitivity by decreasing the CSC subpopulation. The EZH2 inhibition by CPI-1205 or PF-06821497 has been evaluated in combination with other standard treatments in mCRPC and CRPC patients respectively [143]. Moreover, EZH2 inhibition by GSK126 overcomes enzalutamide resistance both *in vitro* and in xenograft PCa models [144]. Finally, trametinib, a MEK1/2 inhibitor approved in melanoma treatment, has been shown to elicit a strong clinical response in mCRPC patients who failed multiple prior treatments [145]. MAPK/ERK signaling pathway is often activated in DCT resistance associated to DCT-miRNAs that affect “survival pathways/apoptosis escape”. It has to be considered that DCT resistance, as well as others drug resistances, is a multifactorial phenomenon that could depend on the predominance of a specific resistant pathway or by the combination of more than one pathway. In these cases, identifying the prevalent pathway/s responsible for DCT resistance could help in selecting the most efficacious compound to be used in combination with post-DCT standard treatment for building personalized therapy. It is also true that different resistant mechanisms share similar pathways (e.g. EMT-CSC, EMT-CSC-survival/apoptosis avoidance pathways, etc.), and, as a consequence, some genes/pathways could represent key hub regulators of DCT resistance and as such they could be the ideal therapeutic targets to use in combination with DCT to limit the risk of resistance.

For all these considerations, the effort of this review was not only to describe the miRNAs involved in docetaxel resistance, but also to classify them, according to regulated target/s and/or affected biological process/es, in a specific pathway/s of docetaxel resistance. It should be also emphasized that improving the knowledge of the molecular networks (composed by coding and non-coding RNA) that contribute to DCT resistance in PCa could also be important in deciphering the resistance mechanisms to other taxanes/treatments in PCa or in different tumor types. Indeed, several DCT-miRNAs also have a role in the resistance to other treatments in PCa. E.g. miR-34a attenuated paclitaxel resistance [146] by regulating the JAG1/NOTCH axis [147]; miR-145 [148] and miR-205 [149] enhanced radiation sensitivity by impairing,

for miR-205, DNA damage repair through PKC ϵ and ZEB1 inhibition; miR-181 [150] and miR-205 [151] decreased and enhanced cisplatin cytotoxicity respectively by inhibiting BAX (miR-181) and by impairing the autophagic flux (miR-205).

Finally, related to the fact that DCT-miRNAs expression levels change in resistant cells/tissues, they could represent useful biomarkers of DCT resistance. Indeed, some of the DCT-miRNAs were measured in human PCa specimens and their potential clinical relevance were demonstrated. In particular, the expression of miR-125a-3p [113], miR-34a-5p [115] and miR-204 [102] significantly decreased in DCT-resistant compared to DCT-sensitive PCa tissues, making them ideal candidate predictive biomarkers. It has to be considered that a biomarker able to detect the early appearance of DCT resistance could greatly help clinicians to select the most efficacious therapy sequence. From this point of view, circulating miRNAs (c-miRNAs) [152–154] represent ideal biomarkers given that they are easy detectable with minimally invasive procedures unlike tissue miRNAs. A few preliminary studies have explored c-miRNAs as DCT predictive biomarkers in PCa patients [155–158]. The increased serum level of miR-21 [155] and miR-210 [156] is potentially predictive of DCT resistance. Interestingly, in a work published in 2017, we demonstrated that miR-210-3p and miR-21-5p were also specifically released by DCT resistant PCa clones compared to parental cells [159]. Recently, Zedan et al. showed that miR-141 and miR-375 plasma levels may predict the progression in mCRPC patients treated with DCT and abiraterone [160].

In conclusion, the increasing knowledge of the molecular networks, including miRNA networks, at the basis of drug resistance mechanisms will be fundamental to drive research toward new therapeutic paradigms for the treatment of cancer type for which, at least at certain stage, current treatments are poorly effective.

Declaration of Competing Interest

The author declares no conflicts of interest.

Acknowledgments

I would like to thank Dr. Marcella Simili, Dr. Letizia Pitto, Dr. Francesca Patella and Dr. Mike Minks for critical reading of the manuscript and Dr. Mike Minks for the revision and language editing of the manuscript. I also would like to thank the reviewers for their helpful comments towards improving the manuscript.

References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA Cancer J. Clin.* 68 (6) (2018) 394–424.
- [2] G. Wang, D. Zhao, D.J. Spring, R.A. DePinho, Genetics and biology of prostate cancer, *Genes Dev.* 32 (17–18) (2018) 1105–1140.
- [3] D.I. Quinn, H.M. Sandler, L.G. Horvath, A. Goldkorn, J.A. Eastham, The evolution of chemotherapy for the treatment of prostate cancer, *Ann. Oncol.* 28 (11) (2017) 2658–2669.
- [4] R. Nader, J. El Amm, J.B. Aragon-Ching, Role of chemotherapy in prostate cancer, *Asian J. Androl.* 20 (3) (2018) 221–229.
- [5] S. Sumanasuriya, J. De Bono, Treatment of advanced prostate cancer—a review of current therapies and future promise, *Cold Spring Harb Persp. Med.* 8 (6) (2018).
- [6] J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R. J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T. W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C. N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher, C. A. Investigators, Abiraterone and increased survival in metastatic prostate cancer, *N. Engl. J. Med.* 364 (21) (2011) 1995–2005.
- [7] H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. S. de Bono, A. Investigators, Increased survival with enzalutamide in prostate cancer after chemotherapy, *N. Engl. J. Med.* 367 (13) (2012) 1187–1197.
- [8] T.M. Beer, B. Tombal, Enzalutamide in metastatic prostate cancer before chemotherapy, *N. Engl. J. Med.* 371 (18) (2014) 1755–1756.
- [9] E. Kopczyńska, Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel, *Contemp Oncol (Pozn)* 19 (6) (2015) 423–427.
- [10] F. Li, R.I. Mahato, MicroRNAs and drug resistance in prostate cancers, *Mol. Pharm.* 11 (8) (2014) 2539–2552.
- [11] A. Razdan, P. de Souza, T.L. Roberts, Role of MicroRNAs in treatment response in prostate cancer, *Curr. Cancer Drug Targets* 18 (10) (2018) 929–944.
- [12] M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, *Nat. Rev. Cancer* 4 (4) (2004) 253–265.
- [13] R.S. Herbst, F.R. Khuri, Mode of action of docetaxel - a basis for combination with novel anticancer agents, *Cancer Treat. Rev.* 29 (5) (2003) 407–415.
- [14] G. Kramer, S. Schwarz, M. Hagg, A.M. Havelka, S. Linder, Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles, *Br. J. Cancer* 94 (11) (2006) 1592–1598.
- [15] F. Fabbri, D. Amadori, S. Carloni, G. Brigliadori, A. Tesi, P. Ulivi, M. Rosetti, I. Vannini, C. Arienti, W. Zoli, R. Silvestrini, Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells, *J. Cell. Physiol.* 217 (2) (2008) 494–501.
- [16] J. Mang, K. Merkle, M. Heller, J. Schuler, Y. Tolstov, J. Li, M. Hohenfellner, S. Duensing, Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells, *Urol. Oncol.* 35 (1) (2017) e9–e16, 32.
- [17] M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Escuin, X.K. Zhou, A. Gjyrezi, C. Chanel-Vos, R. Shen, S.T. Tagawa, N.H. Bander, D.M. Nanus, P. Giannakakou, Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer, *Cancer Res.* 71 (18) (2011) 6019–6029.
- [18] M. Thadani-Mulero, D.M. Nanus, P. Giannakakou, Androgen receptor on the move: boarding the microtubule expressway to the nucleus, *Cancer Res.* 72 (18) (2012) 4611–4615.
- [19] G. Galletti, B.I. Leach, L. Lam, S.T. Tagawa, Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer, *Cancer Treat. Rev.* 57 (2017) 16–27.
- [20] S. Giacinti, G. Poti, M. Roberto, S. Macrini, M. Bassanelli, D.I.P. F. A.M. Aschelter, A. Ceribelli, E.M. Ruggeri, P. Marchetti, Molecular basis of drug resistance and insights for new treatment approaches in mCRPC, *Anticancer Res.* 38 (11) (2018) 6029–6039.
- [21] G. Ploussard, S. Terry, P. Maille, Y. Allory, N. Sirab, L. Kheuang, P. Soyeux, N. Nicolaiew, E. Coppolani, B. Paule, L. Salomon, S. Culine, R. Buttyan, F. Vacherot, A. de la Taille, Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy, *Cancer Res.* 70 (22) (2010) 9253–9264.
- [22] S. Terry, G. Ploussard, Y. Allory, N. Nicolaiew, F. Boissiere-Michot, P. Maille, L. Kheuang, E. Coppolani, A. Ali, F. Bibeau, S. Culine, R. Buttyan, A. de la Taille, F. Vacherot, Increased expression of class III beta-tubulin in castration-resistant human prostate cancer, *Br. J. Cancer* 101 (6) (2009) 951–956.
- [23] T. Hara, K. Ushio, M. Nishiwaki, J. Kouno, H. Araki, Y. Hikichi, M. Hattori, Y. Imai, M. Yamaoka, A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line, *Cell Biol. Int.* 34 (2) (2010) 177–184.
- [24] J. Yang, Y. Yu, W. Liu, Z. Li, Z. Wei, R. Jiang, Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines, *Res. Rep. Urol.* 9 (2017) 71–77.
- [25] M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters, *Nat. Rev. Cancer* 2 (1) (2002) 48–58.
- [26] D.E. Oprea-Lager, I.V. Bijnsdorp, V.A.N.M. R.J. V.D.E. AJ, O.S. Hoekstra, A. A. Geldof, ABCG4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro, *Anticancer Res.* 33 (2) (2013) 387–391.
- [27] Y. Zhu, C. Liu, N. Nadiminty, W. Lou, R. Tummla, C.P. Evans, A.C. Gao, Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer, *Mol. Cancer Ther.* 12 (9) (2013) 1829–1836.
- [28] C. Liu, Z. Li, L. Bi, K. Li, B. Zhou, C. Xu, J. Huang, K. Xu, NOTCH1 signaling promotes chemoresistance via regulating ABCG1 expression in prostate cancer stem cells, *Mol. Cell. Biochem.* 393 (1–2) (2014) 265–270.
- [29] C.A. Martins, G.D.G. Rocha, C.R. Gattass, C.M. Takiya, Pomolic acid exhibits anticancer potential against a docetaxel-resistant PC3 prostate cell line, *Oncol. Rep.* 42 (1) (2019) 328–338.
- [30] L. Magadoux, N. Isambert, S. Plenchette, J.F. Jeannin, V. Laurens, Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review), *Int. J. Oncol.* 45 (3) (2014) 919–928.
- [31] T. Chandrasekar, J.C. Yang, A.C. Gao, C.P. Evans, Mechanisms of resistance in castration-resistant prostate cancer (CRPC), *Transl. Androl. Urol.* 4 (3) (2015) 365–380.
- [32] R. Parrondo, A. de Las Pozas, T. Reiner, C. Perez-Stable, ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimetastatic-mediated apoptosis in human prostate cancer cells, *PeerJ* 1 (2013), e144.
- [33] H. Tamaki, N. Harashima, M. Hiraki, N. Arichi, N. Nishimura, H. Shiina, K. Naora, M. Harada, Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition, *Oncotarget* 5 (22) (2014) 11399–11412.
- [34] S.J. Hotte, Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins, *Future Oncol.* 13 (4) (2017) 369–379.
- [35] J.Y. Djeu, S. Wei, Clusterin and chemoresistance, *Adv. Cancer Res.* 105 (2009) 77–92.
- [36] B. Zhong, D.A. Sallman, D.L. Gilvary, D. Parnazza, E. Sahakian, D. Fritz, J. Q. Cheng, I. Trougakos, S. Wei, J.Y. Djeu, Induction of clusterin by AKT–role in cytoprotection against docetaxel in prostate tumor cells, *Mol. Cancer Ther.* 9 (6) (2010) 1831–1841.

- [37] L.A. Muhammad, F. Saad, The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target, *Expert. Rev. Anticancer. Ther.* 15 (9) (2015) 1049–1061.
- [38] K. Tantivejkul, R.D. Loberg, S.C. Mawocha, L.L. Day, L.S. John, B.A. Pienta, M. A. Rubin, K.J. Pienta, PAR1-mediated NfκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism, *J. Cell. Biochem.* 96 (3) (2005) 641–652.
- [39] P. Toren, A. Zoubeidi, Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review), *Int. J. Oncol.* 45 (5) (2014) 1793–1801.
- [40] S.K. Singh, T. Apata, J.B. Gordetsky, R. Singh, Docetaxel combined with thymoquinone induces apoptosis in prostate cancer cells via inhibition of the PI3K/AKT signaling pathway, *Cancers (Basel)* 11 (9) (2019).
- [41] X. Lu, F. Yang, D. Chen, Q. Zhao, D. Chen, H. Ping, N. Xing, Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways, *Int. J. Biol. Sci.* 16 (7) (2020) 1121–1134.
- [42] S. Zelivianski, M. Spellman, M. Kellerman, V. Kakitelashvili, X.W. Zhou, E. Lugo, M.S. Lee, R. Taylor, T.L. Davis, R. Hauke, M.F. Lin, ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells, *Int. J. Cancer* 107 (3) (2003) 478–485.
- [43] Z. Liu, G. Zhu, R.H. Getzenberg, R.W. Veltri, The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer, *J. Cell. Biochem.* 116 (7) (2015) 1341–1349.
- [44] S.J. Vidal, V. Rodriguez-Bravo, S.A. Quinn, R. Rodriguez-Barrueco, A. Lujambio, E. Williams, X. Sun, J. de la Iglesia-Vicente, A. Lee, B. Readhead, X. Chen, M. Galsky, B. Esteve, D.P. Petrylak, J.T. Dudley, R. Rabadan, J.M. Silva, Y. Hoshida, S.W. Lowe, C. Cordon-Cardo, J. Domingo-Domenech, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer, *Cancer Cell* 27 (2) (2015) 223–239.
- [45] S.R. Plymate, R.S. Bhatt, S.P. Balk, Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2, *Cancer Cell* 27 (2) (2015) 158–159.
- [46] B. Seruga, A. Ocana, I.F. Tannock, Drug resistance in metastatic castration-resistant prostate cancer, *Nat. Rev. Clin. Oncol.* 8 (1) (2011) 12–23.
- [47] M. Thadani-Mulero, L. Portella, S. Sun, M. Sung, A. Matov, R.L. Vessella, E. Corey, D.M. Nanus, S.R. Plymate, P. Giannakakou, Androgen receptor splice variants determine taxane sensitivity in prostate cancer, *Cancer Res.* 74 (8) (2014) 2270–2282.
- [48] G. Zhang, X. Liu, J. Li, E. Ledet, X. Alvarez, Y. Qi, X. Fu, O. Sartor, Y. Dong, H. Zhang, Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents, *Oncotarget* 6 (27) (2015) 23358–23371.
- [49] E.S. Antonarakis, C. Lu, B. Luber, H. Wang, Y. Chen, M. Nakazawa, R. Nadal, C. J. Paller, S.R. Denmeade, M.A. Carducci, M.A. Eisenberger, J. Luo, Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer, *JAMA Oncol.* 1 (5) (2015) 582–591.
- [50] F. Crea, M.A. Duhagon Serrat, E.M. Hurt, S.B. Thomas, R. Danesi, W.L. Farrar, BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer, *Int. J. Cancer* 128 (8) (2011) 1946–1954.
- [51] T. Rabi, A. Bishayee, d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: generation of reactive oxygen species and induction of apoptosis, *J. Carcinog.* 8 (2009) 9.
- [52] G. Varbiro, B. Veres, F. Gallyas Jr., B. Sumegi, Direct effect of Taxol on free radical formation and mitochondrial permeability transition, *Free Radic. Biol. Med.* 31 (4) (2001) 548–558.
- [53] S. Datta, D. Choudhury, A. Das, D. Das Mukherjee, N. Das, S.S. Roy, G. Chakrabarti, Paclitaxel resistance development is associated with biphasic changes in reactive oxygen species, mitochondrial membrane potential and autophagy with elevated energy production capacity in lung cancer cells: a chronological study, *Tumour Biol.* 39 (2) (2017) (1010428317694314).
- [54] D. Zhang, Y. Cui, L. Niu, X. Xu, K. Tian, C.Y. Young, H. Lou, H. Yuan, Regulation of SOD2 and beta-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells, *Eur. J. Cell Biol.* 93 (7) (2014) 289–298.
- [55] Y. Tang, B. Parmakhtiar, A.R. Simoneau, J. Xie, J. Fruehauf, M. Lilly, X. Zi, Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels, *Neoplasia* 13 (2) (2011) 108–119.
- [56] E.S. Antonarakis, A.J. Armstrong, Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer, *Prostate Cancer Prostatic Dis.* 14 (3) (2011) 192–205.
- [57] P. Pucci, P. Rescigno, S. Sumanasuriya, J. de Bono, F. Crea, Hypoxia and noncoding RNAs in taxane resistance, *Trends Pharmacol. Sci.* 39 (8) (2018) 695–709.
- [58] J. van Staalduijn, D. Baker, P. Ten Dijke, H. van Dam, Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? *Oncogene* 37 (48) (2018) 6195–6211.
- [59] H. Manoochchri Khoshinani, S. Afshar, R. Najafi, Hypoxia: a double-edged sword in cancer therapy, *Cancer Investig.* 34 (10) (2016) 536–545.
- [60] X. Jing, F. Yang, C. Shao, K. Wei, M. Xie, H. Shen, Y. Shu, Role of hypoxia in cancer therapy by regulating the tumor microenvironment, *Mol. Cancer* 18 (1) (2019) 157.
- [61] J.M. Farrow, J.C. Yang, C.P. Evans, Autophagy as a modulator and target in prostate cancer, *Nat. Rev. Urol.* 11 (9) (2014) 508–516.
- [62] F. Hu, Y. Zhao, Y. Yu, J.M. Fang, R. Cui, Z.Q. Liu, X.L. Guo, Q. Xu, Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3, *Cancer Lett.* 416 (2018) 24–30.
- [63] J. Zeng, W. Liu, Y.Z. Fan, D.L. He, L. Li, PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy, *Theranostics* 8 (1) (2018) 109–123.
- [64] Q. Wang, W.Y. He, Y.Z. Zeng, A. Hossain, X. Gou, Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells, *Int. Urol. Nephrol.* 50 (4) (2018) 675–686.
- [65] J. Jia, H.B. Zhang, Q. Shi, C. Yang, J.B. Ma, B. Jin, X. Wang, D. He, P. Guo, KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy, *Theranostics* 9 (19) (2019) 5464–5477.
- [66] J.Z. Lin, W.W. Wang, T.T. Hu, G.Y. Zhu, L.N. Li, C.Y. Zhang, Z. Xu, H.B. Yu, H. F. Wu, J.G. Zhu, FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy, *Cancer Lett.* 469 (2020) 481–489.
- [67] S. Luo, L. Shao, Z. Chen, D. Hu, L. Jiang, W. Tang, NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway, *Exp. Cell Res.* 390 (2) (2020) 111981.
- [68] M. Singh, N. Yelle, C. Venugopal, S.K. Singh, EMT: mechanisms and therapeutic implications, *Pharmacol. Ther.* 182 (2018) 80–94.
- [69] S.A. Mani, W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F. Reinhard, C.C. Zhang, M. Shipitsin, L.L. Campbell, K. Polyak, C. Brisken, J. Wang, R.A. Weinberg, The epithelial-mesenchymal transition generates cells with properties of stem cells, *Cell* 133 (4) (2008) 704–715.
- [70] T. Shibue, R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, *Nat. Rev. Clin. Oncol.* 14 (10) (2017) 611–629.
- [71] S. Figiel, C. Vasseur, F. Bruyere, F. Rozet, K. Maheo, G. Fromont, Clinical significance of epithelial-mesenchymal transition markers in prostate cancer, *Hum. Pathol.* 61 (2017) 26–32.
- [72] K.A. Cheaito, H.F. Bahmad, O. Hadadeh, E. Saleh, C. Dagher, M.S. Hammoud, M. Shahait, Z.A. Mrad, S. Nassif, A. Tawil, M. Bulbul, R. Khauli, W. Wazzan, R. Nasr, A. Shamseddine, S. Temraz, M.E. El-Sabban, A. El-Hajj, D. Mukherji, W. Abou-Kheir, EMT markers in locally-advanced prostate cancer: predicting recurrence? *Front. Oncol.* 9 (2019) 131.
- [73] M. Marin-Aguilera, J. Codony-Servat, O. Reig, J.J. Lozano, P.L. Fernandez, M. V. Pereira, N. Jimenez, M. Donovan, P. Puig, L. Mengual, R. Bermudo, A. Font, E. Gallardo, M.J. Ribal, A. Alcaraz, P. Gascon, B. Mellado, Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer, *Mol. Cancer Ther.* 13 (5) (2014) 1270–1284.
- [74] J. Caramel, M. Ligier, A. Puisieux, Pleiotropic roles for ZEB1 in cancer, *Cancer Res.* 78 (1) (2018) 30–35.
- [75] K. Hanrahan, A. O'Neill, M. Prenceip, J. Bugler, L. Murphy, A. Fabre, M. Pühr, Z. Culig, K. Murphy, R.W. Watson, The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer, *Mol. Oncol.* 11 (3) (2017) 251–265.
- [76] O. Orellana-Serradell, D. Herrera, E.A. Castellon, H.R. Contreras, The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines, *Asian J. Androl.* 21 (5) (2019) 460–467.
- [77] E. Batlle, H. Clevers, Cancer stem cells revisited, *Nat. Med.* 23 (10) (2017) 1124–1134.
- [78] M. Prieto-Vila, R.U. Takahashi, W. Usuba, I. Kohama, T. Ochiya, Drug resistance driven by cancer stem cells and their niche, *Int. J. Mol. Sci.* 18 (12) (2017).
- [79] C.J. Lai, C.Y. Lin, W.Y. Liao, T.C. Hour, H.D. Wang, C.P. Chuu, CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of Hippo-Yap Signaling, *Cells* 8 (4) (2019).
- [80] S. Talukdar, S.K. Das, A.K. Pradhan, L. Emdad, J.J. Windle, D. Sarkar, P.B. Fisher, MDA-9/Syntenin (SDCBP) is a critical regulator of chemoresistance, survival and stemness in prostate cancer stem cells, *Cancers (Basel)* 12 (1) (2019).
- [81] S.U. Luk, W.N. Yap, Y.T. Chiu, D.T. Lee, S. Ma, T.K. Lee, R.S. Vasireddy, Y. C. Wong, Y.P. Ching, C. Nelson, Y.L. Yap, M.T. Ling, Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population, *Int. J. Cancer* 128 (9) (2011) 2182–2191.
- [82] M. Gruber, F. Handle, Z. Culig, The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells, *Prostate* 80 (3) (2020) 267–273.
- [83] Y.Q. Liu, S.K. Wang, Q.Q. Xu, H.Q. Yuan, Y.X. Guo, Q. Wang, F. Kong, Z.M. Lin, D. Q. Sun, R.M. Wang, H.X. Lou, Acetyl-11-keto-beta-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties, *Acta Pharmacol. Sin.* 40 (5) (2019) 689–698.
- [84] G. Canesin, V. Maggio, M. Palominos, A. Stiehm, H.R. Contreras, E.A. Castellon, J. Morote, R. Paciucci, N.J. Maitland, A. Bjartell, R. Hellsten, STAT3 inhibition with galliellactone effectively targets the prostate cancer stem-like cell population, *Sci. Rep.* 10 (1) (2020) 13958.
- [85] X.B. Niu, G.B. Fu, L. Wang, X. Ge, W.T. Liu, Y.Y. Wen, H.R. Sun, L.Z. Liu, Z. J. Wang, B.H. Jiang, Insulin-like growth factor-1 induces chemoresistance to docetaxel by inhibiting miR-143 in human prostate cancer, *Oncotarget* 8 (63) (2017) 107157–107166.
- [86] B. Xu, X. Niu, X. Zhang, J. Tao, D. Wu, Z. Wang, P. Li, W. Zhang, H. Wu, N. Feng, Z. Wang, L. Hua, X. Wang, miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS, *Mol. Cell. Biochem.* 350 (1–2) (2011) 207–213.
- [87] W. Gao, S. Lin, C. Cheng, A. Zhu, Y. Hu, Z. Shi, X. Zhang, Z. Hong, Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel, *Arch. Biochem. Biophys.* 665 (2019) 69–78.

- [88] A.B. McKie, D.A. Douglas, S. Olijslagers, J. Graham, M.M. Omar, R. Heer, V. J. Gnanaprasam, C.N. Robson, H.Y. Leung, Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer, *Oncogene* 24 (13) (2005) 2166–2174.
- [89] G.H. Shi, D.W. Ye, X.D. Yao, S.L. Zhang, B. Dai, H.L. Zhang, Y.J. Shen, Y. Zhu, Y. P. Zhu, W.J. Xiao, C.G. Ma, Involvement of microRNA-21 in mediating chemoresistance to docetaxel in androgen-independent prostate cancer PC3 cells, *Acta Pharmacol. Sin.* 31 (7) (2010) 867–873.
- [90] B. Dong, Z. Shi, J. Wang, J. Wu, Z. Yang, K. Fang, IL-6 inhibits the targeted modulation of PDCD4 by miR-21 in prostate cancer, *PLoS One* 10 (8) (2015), e0134366.
- [91] J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, M. Rolfe, J.S. Ross, P. Gascon, J. Albanell, B. Mellado, Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity, *Clin. Cancer Res.* 12 (18) (2006) 5578–5586.
- [92] N. Bhatnagar, X. Li, S.K. Padi, Q. Zhang, M.S. Tang, B. Guo, Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells, *Cell Death Dis.* 1 (2010), e105.
- [93] Q. Zhang, S.K. Padi, D.J. Tindall, B. Guo, Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31, *Cell Death Dis.* 5 (2014), e1486.
- [94] S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M. G. Sada, D. Ghosh, K.J. Pienta, R.G. Sewalt, A.P. Otte, M.A. Rubin, A. M. Chinnaiyan, The polycomb group protein EZH2 is involved in progression of prostate cancer, *Nature* 419 (6907) (2002) 624–629.
- [95] X. Ma, L. Zou, X. Li, Z. Chen, Q. Lin, X. Wu, MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer, *Biomed. Pharmacother.* 99 (2018) 445–450.
- [96] Q. Feng, P. He, Y. Wang, MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer, *Gene* 658 (2018) 152–158.
- [97] Q. Gao, J. Zheng, microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73, *Biomed. Pharmacother.* 97 (2018) 528–534.
- [98] W. Zhou, S. Huang, Q. Jiang, T. Yuan, Suppression of miR-4735-3p in androgen receptor-expressing prostate cancer cells increases cell death during chemotherapy, *Am. J. Transl. Res.* 9 (8) (2017) 3714–3722.
- [99] Y. Wang, R. Lieberman, J. Pan, Q. Zhang, M. Du, P. Zhang, M. Nevalainen, M. Kohli, N.K. Shenoy, H. Meng, M. You, L. Wang, miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1, *Mol. Cancer* 15 (1) (2016) 70.
- [100] H.M. Lin, I. Nikolic, J. Yang, L. Castillo, N. Deng, C.L. Chan, N.K. Yeung, E. Dodson, B. Elsworth, C. Spielman, B.Y. Lee, Z. Boyer, K.J. Simpson, R.J. Daly, L. G. Horvath, A. Swarbrick, MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer, *Sci. Rep.* 8 (1) (2018) 7820.
- [101] C.M. Armstrong, C. Liu, W. Lou, A.P. Lombard, C.P. Evans, A.C. Gao, MicroRNA-181a promotes docetaxel resistance in prostate cancer cells, *Prostate* 77 (9) (2017) 1020–1028.
- [102] G. Wu, J. Wang, G. Chen, X. Zhao, microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1), *Am J. Transl. Res.* 9 (8) (2017) 3599–3610.
- [103] L.Y. Chiu, L.L. Hsin, T.Y. Yang, W.W. Sung, J.Y. Chi, J.T. Chang, J.L. Ko, G. T. Sheu, The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids, *Oncogene* 36 (2) (2017) 242–253.
- [104] Y. Gu, Y. Zhao, Y. Zhou, Y. Xie, P. Ju, Y. Long, J. Liu, D. Ni, F. Cao, Z. Lyu, Z. Mao, J. Hao, Y. Li, Q. Wan, Q. Kanyomse, Y. Liu, D. Ren, Y. Ning, X. Li, Q. Zhou, B. Li, Zeb1 is a potential regulator of Six2 in the proliferation, apoptosis and migration of metanephric mesenchyme cells, *Int. J. Mol. Sci.* 17 (8) (2016).
- [105] X. Wang, B. Yang, B. Ma, The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells, *Cancer Chemother. Pharmacol.* 78 (5) (2016) 1025–1031.
- [106] C. Wu, C. Miao, Q. Tang, X. Zhou, P. Xi, P. Chang, L. Hua, H. Ni, MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression, *J. Cell. Mol. Med.* 24 (3) (2020) 2098–2108.
- [107] K. Sossey-Alaoui, E.F. Plow, miR-138-mediated regulation of KINDLIN-2 expression modulates sensitivity to chemotherapeutics, *Mol. Cancer Res.* 14 (2) (2016) 228–238.
- [108] Y.X. Chen, Y. Wang, C.C. Fu, F. Diao, L.N. Song, Z.B. Li, R. Yang, J. Lu, Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells, *Endocr. Relat. Cancer* 17 (1) (2010) 39–50.
- [109] Y. Dong, O.L. Tan, D. Loessner, C. Stephens, C. Walpole, G.M. Boyle, P.G. Parsons, J.A. Clements, Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma, *Cancer Res.* 70 (7) (2010) 2624–2633.
- [110] D. Xue, H. Lu, H.Y. Xu, C.X. Zhou, X.Z. He, Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12, *J. Cell. Mol. Med.* 22 (6) (2018) 3223–3237.
- [111] H. Liu, X. Song, J. Hou, Z. Zhao, J. Chang, Posttranscriptional regulation of human antigen R by miR-133b enhances docetaxel cytotoxicity through the inhibition of ATP-binding cassette subfamily G member 2 in prostate cancer cells, *DNA Cell Biol.* 37 (3) (2018) 210–219.
- [112] M. Wu, C.W.S. Tong, W. Yan, K.K.W. To, W.C.S. Cho, The RNA binding protein HuR: a promising drug target for anticancer therapy, *Curr. Cancer Drug Targets* 19 (5) (2019) 382–399.
- [113] J.Z. Liu, F.Y. Yin, C.Y. Yan, H. Wang, X.H. Luo, Regulation of docetaxel sensitivity in prostate cancer cells by hsa-miR-125a-3p via modulation of metastasis-associated protein 1 signaling, *Urology* 105 (2017) e11–e17, 208.
- [114] X. Jiang, S. Guo, Y. Zhang, Y. Zhao, X. Li, Y. Jia, Y. Xu, B. Ma, LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p, *Cell. Signal.* 65 (2020) 109422.
- [115] Y. Ma, B. Fan, Z. Ren, B. Liu, Y. Wang, Long noncoding RNA DANCER contributes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway, *Onco Targets Ther.* 12 (2019) 5485–5497.
- [116] Z. Yang, J.S. Chen, J.K. Wen, H.T. Gao, B. Zheng, C.B. Qu, K.L. Liu, M.L. Zhang, J. F. Gu, J.D. Li, Y.P. Zhang, W. Li, X.L. Wang, Y. Zhang, Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel, *J. Exp. Clin. Cancer Res.* 36 (1) (2017) 178.
- [117] S.W. Ryter, J. Alam, A.M. Choi, Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications, *Physiol. Rev.* 86 (2) (2006) 583–650.
- [118] M. Pühr, J. Hoefler, G. Schafer, H.H. Erb, S.J. Oh, H. Klocker, I. Heidegger, H. Neuwirt, Z. Culig, Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205, *Am. J. Pathol.* 181 (6) (2012) 2188–2201.
- [119] G. Zhang, X. Tian, Y. Li, Z. Wang, X. Li, C. Zhu, miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1, *Biomed. Pharmacother.* 97 (2018) 736–744.
- [120] X. Qiu, W. Wang, B. Li, B. Cheng, K. Lin, J. Bai, H. Li, G. Yang, Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells, *BMC Cancer* 19 (1) (2019) 27.
- [121] J. Yu, Y. Lu, D. Cui, E. Li, Y. Zhu, Y. Zhao, F. Zhao, S. Xia, miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1, *Oncol. Rep.* 31 (2) (2014) 910–918.
- [122] C. Liu, L. Zhang, Y. Huang, K. Lu, T. Tao, S. Chen, X. Zhang, H. Guan, M. Chen, B. Xu, MicroRNA328 directly targets p21activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity, *Mol. Med. Rep.* 12 (5) (2015) 7389–7395.
- [123] X. Wen, X. Li, B. Liao, Y. Liu, J. Wu, X. Yuan, B. Ouyang, Q. Sun, X. Gao, Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel, *Urology* 73 (6) (2009) 1407–1411.
- [124] B. Dummler, K. Ohshiro, R. Kumar, J. Field, Pak protein kinases and their role in cancer, *Cancer Metastasis Rev.* 28 (1–2) (2009) 51–63.
- [125] S. Rezaei, M. Mahjoubin Tehran, A. Sahebkar, A. Jalili, S.H. Aghaee-Bakhtiari, Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance, *J. Cell. Physiol.* 235 (4) (2020) 3222–3234.
- [126] L. Zhang, X. Li, Y. Chao, R. He, J. Liu, Y. Yuan, W. Zhao, C. Han, X. Song, KLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer, *Cell Commun. Signal* 16 (1) (2018) 53.
- [127] Y. Fujita, K. Kojima, R. Ohhashi, N. Hamada, Y. Nozawa, A. Kitamoto, A. Sato, S. Kondo, T. Kojima, T. Deguchi, M. Ito, MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression, *J. Biol. Chem.* 285 (25) (2010) 19076–19084.
- [128] J. He, M. Sun, H. Geng, S. Tian, Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p, *Biol. Cell.* 111 (2) (2019) 39–50.
- [129] Z. Xu, Y. Zhang, J. Ding, W. Hu, C. Tan, M. Wang, J. Tang, Y. Xu, miR-17-3p downregulates mitochondrial antioxidant enzymes and enhances the radiosensitivity of prostate cancer cells, *Mol. Ther. Nucl. Acids* 13 (2018) 64–77.
- [130] H. Gu, M. Liu, C. Ding, X. Wang, R. Wang, X. Wu, R. Fan, Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1, *Cancer Med.* 5 (6) (2016) 1174–1182.
- [131] R. El Bezawy, D. Cominetti, N. Fenderico, V. Zuco, G.L. Beretta, M. Dugo, A. Arrighetti, C. Stucchi, T. Rancati, R. Valdagni, N. Zaffaroni, P. Gandellini, miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis, *Cancer Lett.* 395 (2017) 53–62.
- [132] F. Wang, A. Mao, J. Tang, Q. Zhang, J. Yan, Y. Wang, C. Di, L. Gan, C. Sun, H. Zhang, microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells, *J. Cell. Physiol.* 234 (8) (2019) 13182–13190.
- [133] R. Rupaimoole, F.J. Slack, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, *Nat. Rev. Drug Discov.* 16 (3) (2017) 203–222.
- [134] N. Hosseinahli, M. Aghapour, P.H.G. Duijf, B. Baradaran, Treating cancer with microRNA replacement therapy: a literature review, *J. Cell. Physiol.* 233 (8) (2018) 5574–5588.
- [135] A. Ganju, S. Khan, B.B. Hafeez, S.W. Behrman, M.M. Yallapu, S.C. Chauhan, M. Jaggi, miRNA nanotherapeutics for cancer, *Drug Discov Today* 22 (2) (2017) 424–432.
- [136] S. Boca, D. Gulei, A.A. Zimta, A. Onaciu, L. Magdo, A.B. Tigiu, C. Ionescu, A. Irimie, R. Buiga, I. Berindan-Neagoe, Nanoscale delivery systems for microRNAs in cancer therapy, *Cell. Mol. Life Sci.* 77 (6) (2020) 1059–1086.
- [137] P.K.B. Nagesh, P. Chowdhury, E. Hataami, V.K.N. Boya, V.K. Kashyap, S. Khan, B. B. Hafeez, S.C. Chauhan, M. Jaggi, M.M. Yallapu, miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy, *Cancers (Basel)* 10 (9) (2018).
- [138] F. Lin, D. Wen, X. Wang, R.I. Mahato, Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer, *Biomaterials* 192 (2019) 95–108.

- [139] A. Emmanouilidi, I. Casari, B. Gokcen Akkaya, T. Maffucci, L. Furic, F. Guffanti, M. Broggin, X. Chen, Y.Y. Maxuitenko, A.B. Keeton, G.A. Piazza, K.J. Linton, M. Falasca, Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy, *Cancers (Basel)* 12 (8) (2020).
- [140] S. Meidhof, S. Brabletz, W. Lehmann, B.T. Preca, K. Mock, M. Ruh, J. Schuler, M. Berthold, A. Weber, U. Burk, M. Lubbert, M. Puhr, Z. Culig, U. Wellner, T. Keck, P. Bronsert, S. Kusters, U.T. Hopt, M.P. Stemmler, T. Brabletz, ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat, *EMBO Mol. Med.* 7 (6) (2015) 831–847.
- [141] T.M. Beer, S.J. Hotte, F. Saad, B. Alekseev, V. Matveev, A. Flechon, G. Gravis, F. Joly, K.N. Chi, Z. Malik, B. Blumenstein, P.S. Stewart, C.A. Jacobs, K. Fizazi, Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial, *Lancet Oncol.* 18 (11) (2017) 1532–1542.
- [142] B. Jung-Hynes, M. Nihal, W. Zhong, N. Ahmad, Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? *J. Biol. Chem.* 284 (6) (2009) 3823–3832.
- [143] F. Saad, N. Shore, T. Zhang, S. Sharma, H.K. Cho, I.A. Jacobs, Emerging therapeutic targets for patients with advanced prostate cancer, *Cancer Treat. Rev.* 76 (2019) 1–9.
- [144] Y. Bai, Z. Zhang, L. Cheng, R. Wang, X. Chen, Y. Kong, F. Feng, N. Ahmad, L. Li, X. Liu, Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer, *J. Biol. Chem.* 294 (25) (2019) 9911–9923.
- [145] N.G. Nickols, R. Nazarian, S.G. Zhao, V. Tan, V. Uzunangelov, Z. Xia, R. Baertsch, E. Neeman, A.C. Gao, G.V. Thomas, L. Howard, A.M. De Hoedt, J. Stuart, T. Goldstein, K. Chi, M.E. Gleave, J.N. Graff, T.M. Beer, J.M. Drake, C.P. Evans, R. Aggarwal, A. Foye, F.Y. Feng, E.J. Small, W.J. Aronson, S.J. Freedland, O. N. Witte, J. Huang, J.J. Alumkal, R.E. Reiter, M.B. Rettig, MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer, *Prostate Cancer Prostatic Dis.* 22 (4) (2019) 531–538.
- [146] K. Kojima, Y. Fujita, Y. Nozawa, T. Deguchi, M. Ito, MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms, *Prostate* 70 (14) (2010) 1501–1512.
- [147] X. Liu, X. Luo, Y. Wu, D. Xia, W. Chen, Z. Fang, J. Deng, Y. Hao, X. Yang, T. Zhang, L. Zhou, Y. Wu, Q. Wang, J. Xu, X. Hu, L. Li, MicroRNA-34a attenuates paclitaxel resistance in prostate cancer cells via direct suppression of JAG1/Notch1 Axis, *Cell. Physiol. Biochem.* 50 (1) (2018) 261–276.
- [148] P. Gong, T. Zhang, D. He, J.T. Hsieh, MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer, *Radiat. Res.* 184 (6) (2015) 630–638.
- [149] R. El Bezawy, S. Tinelli, M. Tortoreto, V. Doldi, V. Zucco, M. Folini, C. Stucchi, T. Rancati, R. Valdagni, P. Gandellini, N. Zaffaroni, miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCepsilon and ZEB1 inhibition, *J. Exp. Clin. Cancer Res.* 38 (1) (2019) 51.
- [150] Z.P. Cai, S.J. Tong, Y.P. Wu, L.X. Qu, Q. Ding, miR-181 regulation of BAX controls cisplatin sensitivity of prostate cancer cells, *Int. J. Clin. Exp. Pathol.* 10 (9) (2017) 10127–10133.
- [151] M. Pennati, A. Lopergolo, V. Profumo, M. De Cesare, S. Sbarra, R. Valdagni, N. Zaffaroni, P. Gandellini, M. Folini, miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells, *Biochem. Pharmacol.* 87 (4) (2014) 579–597.
- [152] E. Endzelins, V. Melne, Z. Kalnina, V. Lietuvielis, U. Riekstina, A. Llorente, A. Line, Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review, *Mol. Cancer* 15 (1) (2016) 41.
- [153] X. Filella, L. Foj, miRNAs as novel biomarkers in the management of prostate cancer, *Clin. Chem. Lab. Med.* 55 (5) (2017) 715–736.
- [154] C. Hoey, S.K. Liu, Circulating blood miRNAs for prostate cancer risk stratification: mirroring the underlying tumor biology with liquid biopsies, *Res. Rep. Urol.* 11 (2019) 29–42.
- [155] H.L. Zhang, L.F. Yang, Y. Zhu, X.D. Yao, S.L. Zhang, B. Dai, Y.P. Zhu, Y.J. Shen, G. H. Shi, D.W. Ye, Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy, *Prostate* 71 (3) (2011) 326–331.
- [156] H.H. Cheng, P.S. Mitchell, E.M. Kroh, A.E. Dowell, L. Chery, J. Siddiqui, P. S. Nelson, R.L. Vessella, B.S. Knudsen, A.M. Chinnaiyan, K.J. Pienta, C. Morrissey, M. Tewari, Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia, *PLoS One* 8 (7) (2013), e69239.
- [157] H.M. Lin, L. Castillo, K.L. Mahon, K. Chiam, B.Y. Lee, Q. Nguyen, M.J. Boyer, M. R. Stockler, N. Pavlakis, G. Marx, G. Mallesara, H. Gurney, S.J. Clark, A. Swarbrick, R.J. Daly, L.G. Horvath, Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer, *Br. J. Cancer* 110 (10) (2014) 2462–2471.
- [158] H.M. Lin, K.L. Mahon, C. Spielman, H. Gurney, G. Mallesara, M.R. Stockler, P. Bastick, K. Briscoe, G. Marx, A. Swarbrick, L.G. Horvath, Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer, *Br. J. Cancer* 116 (8) (2017) 1002–1011.
- [159] L. Bascetta, A. Oliviero, R. D'Aurizio, M. Evangelista, A. Mercatanti, M. Pellegrini, F. Marrocolo, S. Bracarda, M. Rizzo, The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance, *Int. J. Mol. Sci.* 18 (7) (2017).
- [160] A.H. Zedan, P.J.S. Othter, J. Assenholts, J.S. Madsen, T.F. Hansen, Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer, *Sci. Rep.* 10 (1) (2020) 227.